Astrana Health, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.18B | $2.03B | $1.39B | $1.14B | $773.9M | $687.2M | $560.6M |
| Cost of Revenue | — | — | — | — | — | $596.1M | $539.2M | $467.8M |
| Gross Profit | — | — | — | — | — | $177.8M | $148.0M | $92.8M |
| Gross Margin | — | — | — | — | — | 23.0% | 21.5% | 16.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $217.3M | $154.1M | $112.6M | $77.7M | $62.1M | $49.1M | $41.5M |
| Operating Income | — | $78.5M | $89.4M | $84.6M | $104.3M | $98.2M | $80.5M | $32.4M |
| Operating Margin | — | 2.5% | 4.4% | 6.1% | 9.1% | 12.7% | 11.7% | 5.8% |
| Interest Expense | — | — | — | $16.1M | $7.9M | $5.4M | $9.5M | $4.7M |
| Pretax Income | — | $39.6M | $80.8M | $89.8M | $86.6M | $77.7M | $178.4M | $25.8M |
| Income Tax Expense | — | $15.5M | $30.9M | $32.0M | $40.9M | $31.7M | $56.3M | $8.2M |
| Net Income | — | $22.5M | $43.1M | $60.7M | $45.2M | $68.9M | $37.7M | $14.1M |
| Net Margin | — | 0.7% | 2.1% | 4.4% | 3.9% | 8.9% | 5.5% | 2.5% |
| EPS (Basic) | — | $0.46 | $0.91 | $1.30 | $1.00 | $1.57 | $1.03 | $0.41 |
| EPS (Diluted) | — | $0.46 | $0.90 | $1.29 | $0.99 | $1.52 | $1.01 | $0.39 |
| Shares Outstanding (Basic) | 55.6M | 49.1M | 47.6M | 46.6M | 45.0M | 43.8M | 36.5M | 34.7M |
| Shares Outstanding (Diluted) | 55.6M | 49.4M | 48.0M | 46.9M | 45.6M | 45.4M | 37.4M | 36.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |